Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,022.02 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗

February 26, 2026

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

The Great Recalibration: Investors Pivot from Silicon Dreams to Industrial Reality

February 26, 2026

As the bull market of the mid-2020s enters a more mature and discerning phase, a profound shift is unfolding across global trading floors. The speculative fervor that once propelled "AI darlings" to...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The maker of Wegovy hasn't said its last words just yet.

Via The Motley Fool

Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗

February 26, 2026

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

Via The Motley Fool

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 ↗

February 26, 2026

Eli Lilly shares rise after orforglipron beats Novo's drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results.

Via Benzinga

The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier

February 26, 2026

As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The...

Via MarketMinute

Topics Artificial Intelligence Economy

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Alphabet Inc. (GOOGL) Deep Dive: Navigating the Agentic Era and the $180 Billion AI Bet

February 26, 2026

As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Workforce

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Via The Motley Fool

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗

February 26, 2026

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Via Stocktwits

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 25, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Via The Motley Fool

Topics Stocks

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Via The Motley Fool

Labor Resilience Defies 'Soft Landing' Narrative: ADP Pulse Data Shows Four Weeks of Growth, Forcing Fed Rethink

February 25, 2026

The U.S. labor market is flashing a surprising signal of late-cycle strength as the shortest month of the year comes to a close. Despite a lukewarm monthly headline in early February, the latest ADP...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗

February 25, 2026

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

Via The Motley Fool

Topics Economy

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗

February 25, 2026

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.

Via Benzinga

Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect

February 25, 2026

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗

February 25, 2026

It would be a near-miracle gain.

Via The Motley Fool

Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

February 24, 2026

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect.

Via StockStory

Topics World Trade

Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect

February 24, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect.

Via StockStory

Topics World Trade

Why Eli Lilly Stock Slumped Today ↗

February 24, 2026

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Via The Motley Fool

Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA ↗

February 24, 2026

Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.

Via Stocktwits

A Tale of Two Titans: Eli Lilly Surges as Novo Nordisk Stumbles in the Weight Loss Price War

February 24, 2026

The global pharmaceutical landscape underwent a seismic shift today, February 24, 2026, as the two pioneers of the weight loss drug revolution reported vastly different outlooks for the coming year....

Via MarketMinute

Stock-Split Watch: Is Meta Platforms Next? ↗

February 24, 2026

Meta is the only "Magnificent Seven" stock that has not had a stock split.

Via The Motley Fool

Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation

February 24, 2026

As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4...

Via Finterra

Topics Earnings Economy Initial Public Offering

Is Johnson & Johnson Stock Outperforming the Nasdaq?

February 24, 2026

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.